Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
PYXS Analyst Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PYXS Stock 12 Month Forecast
Average Price Target
$6.67
▲(390.44% Upside)
| Highest Price Target$8.00 | Average Price Target$6.67 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$5
Buy
267.65%
Upside
Reiterated
08/19/25
Analysts' Top Healthcare Picks: Pyxis Oncology (PYXS), Biohaven Ltd. (BHVN)Valuation and Risks. We maintain our Buy rating and our 12-month price target of $5.00 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from MICVO (formerly PYX-201), assuming a 14% discount rate and a 0% terminal growth rate.
LifeSci Capital
―
Buy
―
Reiterated
08/19/25
Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck CollaborationLast week, Pyxis Oncology reported Q2 2025 earnings and provided an update on its pipeline with micvotabart pelidon (MICV O, PYX-201), its ADC targeted to extra-domain B [EDB] of fibronecn [FN] in the tumor stroma for solid tumors; as a reminder, we saw inial data in November (LINK) from the Phase 1 dose escalaon study with MICVO, where there was an efficacy signal in head and neck squamous cell carcinoma (HNSCC) paen ts that stood out from other tumor types (HNSCC data updated in Feb. 2025, Figure 1, with company posioning in Figure 2). Given the efficacy signal in HNSCC paen ts, Pyxis shared plans to develop MICVO in this paen t populaon going forward (and other solid tumors including HR+/HER2- breast cancer and TNBC, where dose-escalaon with 3 different doses of MICVO + the standard dose of Keytruda is ongoing, with dose selecon expected in mid- 2025).
William Blair
―
Hold
―
Reiterated
08/15/25
Leerink Partners
$7
Buy
414.71%
Upside
Reiterated
08/15/25
Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial PositionWe think the catalyst has an attractive upside-skewed risk-reward for PYXS (OP) that is underappreciated by investors. We see upside/ downside scenarios of +150% / -25% for the two 2H25 catalysts, with risk-reward skewed heavily to the upside given (1) our positive outlook on micvo’s potential SCCHN opportunity; and (2) extremely low investor expectations for the catalyst, as reflected by PYXS’s depressed valuation and negative enterprise value ($70M market cap and ~-$20M EV).
RBC Capital
$8
Buy
488.24%
Upside
Reiterated
08/14/25
TR | OpenAI - 4o
―
Hold
―
Reiterated
05/03/25
Stifel Nicolaus
$10
Buy
635.29%
Upside
Reiterated
03/21/25
Citi
$5
Buy
267.65%
Upside
Reiterated
03/18/25
Jefferies
$12→$6
Buy
341.18%
Upside
Reiterated
03/18/25
Stephens
$13
Buy
855.88%
Upside
Initiated
11/07/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$5
Buy
267.65%
Upside
Reiterated
08/19/25
Analysts' Top Healthcare Picks: Pyxis Oncology (PYXS), Biohaven Ltd. (BHVN)Valuation and Risks. We maintain our Buy rating and our 12-month price target of $5.00 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from MICVO (formerly PYX-201), assuming a 14% discount rate and a 0% terminal growth rate.
LifeSci Capital
―
Buy
―
Reiterated
08/19/25
Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck CollaborationLast week, Pyxis Oncology reported Q2 2025 earnings and provided an update on its pipeline with micvotabart pelidon (MICV O, PYX-201), its ADC targeted to extra-domain B [EDB] of fibronecn [FN] in the tumor stroma for solid tumors; as a reminder, we saw inial data in November (LINK) from the Phase 1 dose escalaon study with MICVO, where there was an efficacy signal in head and neck squamous cell carcinoma (HNSCC) paen ts that stood out from other tumor types (HNSCC data updated in Feb. 2025, Figure 1, with company posioning in Figure 2). Given the efficacy signal in HNSCC paen ts, Pyxis shared plans to develop MICVO in this paen t populaon going forward (and other solid tumors including HR+/HER2- breast cancer and TNBC, where dose-escalaon with 3 different doses of MICVO + the standard dose of Keytruda is ongoing, with dose selecon expected in mid- 2025).
William Blair
―
Hold
―
Reiterated
08/15/25
Leerink Partners
$7
Buy
414.71%
Upside
Reiterated
08/15/25
Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial PositionWe think the catalyst has an attractive upside-skewed risk-reward for PYXS (OP) that is underappreciated by investors. We see upside/ downside scenarios of +150% / -25% for the two 2H25 catalysts, with risk-reward skewed heavily to the upside given (1) our positive outlook on micvo’s potential SCCHN opportunity; and (2) extremely low investor expectations for the catalyst, as reflected by PYXS’s depressed valuation and negative enterprise value ($70M market cap and ~-$20M EV).
RBC Capital
$8
Buy
488.24%
Upside
Reiterated
08/14/25
TR | OpenAI - 4o
―
Hold
―
Reiterated
05/03/25
Stifel Nicolaus
$10
Buy
635.29%
Upside
Reiterated
03/21/25
Citi
$5
Buy
267.65%
Upside
Reiterated
03/18/25
Jefferies
$12→$6
Buy
341.18%
Upside
Reiterated
03/18/25
Stephens
$13
Buy
855.88%
Upside
Initiated
11/07/24
Best Analysts Covering Pyxis Oncology
1 Month
xxx
Success Rate
5/10 ratings generated profit
Average Return
-2.91%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -2.91% per trade.
3 Months
xxx
Success Rate
5/11 ratings generated profit
Average Return
-2.76%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of -2.76% per trade.
1 Year
Success Rate
6/11 ratings generated profit
Average Return
+2.91%
reiterated a buy rating 10 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +2.91% per trade.
2 Years
xxx
Success Rate
3/10 ratings generated profit
Average Return
-41.64%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.00% of your transactions generating a profit, with an average return of -41.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PYXS Analyst Recommendation Trends
Rating
Jan 25
Mar 25
Apr 25
May 25
Aug 25
Strong Buy
10
6
4
7
6
Buy
5
3
2
2
1
Hold
6
4
5
5
3
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
22
14
11
14
10
Each month's total comprises the sum of three months' worth of ratings.
PYXS Financial Forecast
PYXS Stock Forecast FAQ
What is PYXS’s average 12-month price target, according to analysts?
Based on analyst ratings, Pyxis Oncology’s 12-month average price target is 6.67.
What is PYXS’s upside potential, based on the analysts’ average price target?
Pyxis Oncology has 390.44% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PYXS a Buy, Sell or Hold?
Pyxis Oncology has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Pyxis Oncology’s price target?
The average price target for Pyxis Oncology is 6.67. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $5.00. The average price target represents 390.44% Increase from the current price of $1.36.
The highest analyst price target is $8.00 ,the lowest forecast is $5.00. The average price target represents 390.44% Increase from the current price of $1.36.
What do analysts say about Pyxis Oncology?
Pyxis Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of PYXS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.